Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from REGN

Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?

Despite Vertex Pharmaceuticals' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Barchart

Is Regeneron Pharmaceuticals Stock Underperforming the Dow?

Regeneron Pharmaceuticals has underperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.

Barchart

Are Wall Street Analysts Predicting Regeneron Pharmaceuticals Stock Will Climb or Sink?

Regeneron Pharmaceuticals has underperformed the broader market over the past year, and analysts remain reasonably bullish about the stock’s long term prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.

Regeneron stock sinks as fianlimab Phase 3 trial fails to meet primary endpoint. But RBC continues to see significant upside in REGN shares from here.

Barchart

Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report

Regeneron Pharmaceuticals is expected to announce its fiscal first-quarter earnings this month, and analysts project a low single-digit earnings drop.

Barchart

Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Although Regeneron Pharmaceuticals has lagged the Nasdaq over the past year, analysts remain highly bullish about its prospects.

Barchart

Is Wall Street Bullish or Bearish on Regeneron Pharmaceuticals Stock?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and analysts remain highly upbeat about the stock’s growth potential.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Regeneron Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know

Regeneron Pharmaceuticals will release its fourth-quarter earnings later this month, and analysts anticipate a double-digit profit dip.

Barchart

Is Regeneron Pharmaceuticals Stock Underperforming the S&P 500?

Regeneron Pharmaceuticals has underperformed the S&P 500 over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Barchart

Are Wall Street Analysts Bullish on Regeneron Pharmaceuticals Stock?

Regeneron Pharmaceuticals has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Tuesday reported third-quarter adjusted earnings of $11.83 per share, down 5% year-over-year, beating the consensus of $9.59.

Benzinga

Regeneron’s Q3 2025 Earnings: What to Expect

Regeneron is expected to announce its fiscal third-quarter earnings later this month, and analysts project a double-digit earnings decline.

Barchart

Regeneron's Gene Therapy Shows Significant Gains In Genetic Hearing Loss

On Sunday, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) unveiled updated data from its investigational gene therapy DB-OTO for profound genetic hearing loss caused by variants of the otoferlin (OTOF) gene.

Benzinga

Regeneron's Libtayo Gains FDA Approval To Reduce Recurrence Risk In Skin Cancer Patients

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) PD-1 inhibitor Libtayo (cemiplimab-rwlc) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

FDA Expands Use Of Regeneron's Evkeeza To Infants With Rare Cholesterol Disorder

The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals, Inc.’s (NASDAQ: REGN) Evkeeza (evinacumab-dgnb) ANGPTL3 antibody as an adjunct to diet and exercise and other lipid-lowering therapies for the treatment of children from age 1 to less than 5 years old with homozygous familial hypercholesterolemia (HoFH).

Benzinga

FDA Delays Key Sanofi Multiple Sclerosis Drug Decision

On Monday, the U.S. Food and Drug Administration (FDA) extended the review date for Sanofi SA’s (NASDAQ:SNY) new drug application (NDA) of tolebrutinib for non-relapsing, secondary progressive multiple sclerosis (nrSPMS) and to slow disability accumulation independent of relapse activity in adult patients.

Benzinga

Regeneron Touts Positive Data From Phase 3 Study In Patients With Ultra-Rare Genetic Disorder

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported positive results from its Phase 3 OPTIMA trial of garetosmab in adults with fibrodysplasia ossificans progressiva (FOP), meeting the study's primary endpoint.

Benzinga

Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday announced five-year follow-up results on overall survival (OS) from the Phase 3 EMPOWER-Lung 3 trial of Libtayo (cemiplimab) plus platinum-based chemotherapy versus chemotherapy alone as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with no EGFR, ALK,…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

What's Happening With Regeneron Pharmaceuticals Stock On Monday?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) revealed data from Phase 3 trials in adults with moderate-to-severe cat or birch allergies on Monday. Both trials met their respective primary and key secondary endpoints.

Barchart

Is Vertex Pharmaceuticals Stock Underperforming the S&P 500?

Vertex Pharmaceuticals has lagged the broader S&P 500 Index over the past year, but Wall Street analysts remain moderately optimistic about the company’s long-term prospects.

Barchart

How Is Regeneron’s Stock Performance Compared to Other Pharma Stocks?

Regeneron Pharmaceuticals has significantly underperformed the broader pharma space over the past year, yet analysts remain optimistic about the stock’s prospects.

Barchart

What Are Wall Street Analysts’ Target Price for Regeneron Pharmaceuticals Stock?

Regeneron’s stock has fallen behind the broader market over the past year, but analysts see potential for growth, tempered with caution.

Benzinga

Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday shared data from the Phase 3 NIMBLE trial assessing investigational cemdisiran monotherapy in adults with generalized myasthenia gravis (gMG).

Barchart

Worried About a Market Crash? Here Are 3 Stocks That ‘Big Short’ Star Michael Burry Loves Here.

Here are three top stocks that the ‘Big Short’ star Michael Burry owns in Q2 of 2025. Are UNH, REGN, and LULU undervalued right now?

The Guardian - UK

Ditch your dish sponge, take a packed lunch: 33 easy plastic-free kitchen swaps

Plastic is a growing concern, so it’s time to cut back. Here’s how, from tips on reducing our use to ideas for more sustainable products

1 2 3 4 5

People

Michael Burry

313 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Regeneron Pharmaceuticals

65 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.